FDA expands use of Imbruvica to treat rare form of blood cancer

January 29, 2015 6:12 PM

5 0

(Reuters) - The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists.

The regulator's decision, which comes in over two months ahead of its review date, represents a fourth indication for the drug, sold by Johnson & Johnson and Pharmacyclics Inc.

Read more

To category page

Loading...